RC108 + furmonertinib + toripalimab

RC108 + furmonertinib + toripalimab is a combination regimen under clinical investigation for advanced non-small cell lung cancer (NSCLC). - RC108 is an investigational agent, though its full details and mechanism are less widely characterized in public databases. - Furmonertinib (AST2818, Alflutinib) is a third-generation, orally administered, brain-penetrant, mutation-selective small molecule tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and HER2 mutations. It is approved in China for NSCLC with specific EGFR mutations, and demonstrates broad activity across EGFR activating, T790M, and exon 20 insertion mutations, as well as preclinical activity against HER2 exon 20 insertions[1][2][3]. - Toripalimab is a monoclonal antibody inhibitor of programmed death-1 (PD-1), used as an immune checkpoint inhibitor to restore anti-tumor immunity. This combination regimen aims to unite targeted therapy (furmonertinib), frontline immunotherapy (toripalimab), and RC108 to address resistant or unresponsive NSCLC. - Primary indication for this combination is advanced or metastatic non-small cell lung cancer (NSCLC), especially with relevant EGFR or HER2 mutations. - See comments below for study/trial details and investigational context.

Brand names

RC108 + furmonertinib + toripalimab

Other names

RC108 + furmonertinib + toripalimab